Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

Fig. 6

Relevance of SH3BGRL with pHER2 (Y1196) in breast cancer tissues. a Representative immunohistochemistry staining of SH3BGRL and p-HER2 (Y1196) expression in serial sections (left panel), and the statistical analyses of their expressions in tumor tissues and their matched adjacent ones from breast cancer patient. b Spearman correlation analysis showed that there is a significant positive correlation between the expression of SH3BGRL and pHER2 (Y1196): r = 0.7524, p < 0.0001. c Statistical analysis of 76 HER2-positive breast cancer cases in tissue microarray after immunohistochemistry detection of SH3BGRL and HER2 expression. d Kaplan-Meier survival analyses of SH3BGRL expression to 1075 breast cancer patients from THE HUMAN PROTEIN ATLAS. The log-rank test p values are shown. e Kaplan-Meier survival analyses of the 10-year survival rate in 198 patients with high HER2 expression from above dataset. The log-rank test p values are shown. f Kaplan-Meier survival analyses of 936 patients from above TCGA Pan-Cancer Clinical Data Resource data with SH3BGRL expression and the progression free survival rate. The log-rank test p values are shown

Back to article page